TWi Pharmaceuticals, Inc. Announced The Promotion Of R&D EVP Jianbo Xie As COO

TAIPEI, May 14, 2015 /PRNewswire/ -- TWi Pharmaceuticals, Inc. ("TWi") (Stock Ticker:4180.TT) announced that its R&D Executive Vice President (EVP) Mr. Jianbo Xie was promoted to Chief Operating Officer (COO) effective immediately. The reorganization is intended for better efficiency and maximal output for TWi's team in Taiwan. In addition to being responsible for his existing R&D function, Mr. Xie will also be responsible for Production in Chungli and Operations in Neihu headquarters.

With EVP & COO Jianbo Xie being responsible for Taiwan R&D and related operations, together with President & CEO Tina Guilder responsible for commercialization, financial and corporate development, and overall operating performance, TWi will be moving toward another milestone; stronger R&D, growing commercialization, and a sustainable enterprise.

About TWi Pharmaceuticals, Inc.

TWi Pharmaceuticals, Inc. is a leading specialty pharmaceutical company based in Taipei, Taiwan, focusing on the development of high barrier generic prescription products ranging from oral controlled release dosage form to novel drug delivery systems including the utilization of nanoparticles, transdermal, and polymeric oral delivery systems. Leveraging its internal research and development capabilities, together with operational flexibility, process development, manufacturing and regulatory expertise, TWi Pharmaceuticals concentrates on products and technologies that present significant barriers to entry or offer Paragraph IV first-to-file or first-to-market opportunities in the United States. For more information of TWi Pharmaceuticals, please visit www.twipharma.com.

Contact:

Eric Lin
Investor Relations
Tel: +886-2-2657-3350 ext. 407
Email: [email protected]

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/twi-pharmaceuticals-announced-the-promotion-of-rd-evp-jianbo-xie-as-coo-300083380.html

SOURCE TWi Pharmaceuticals, Inc.

Suggested Articles

The biotech behind AstraZeneca and the University of Oxford’s late-stage pandemic vaccine has hired Margaret (Meg) Marshall, M.D., as its new CMO.

On the heels of a merger and $60 million private offering, Compass is looking to go public. It filed to raise up to $50 million in its Nasdaq IPO.

he results suggest V114 provides broader protection from pneumococcal bacteria than Prevnar 13 does, positioning Merck to muscle in on Pfizer’s turf.